Rob Steendam, PhD, is co-founder and Chief Technology Officer at InnoCore Pharmaceuticals, a biopharmaceutical drug delivery company specialized in the development of long-acting injectables for the treatment of chronic and site-specific diseases. At InnoCore he heads the development of InnoCore’s innovative biodegradable polymeric sustained release drug delivery technologies and oversees the execution of InnoCore’s partnered drug delivery product development programs. He is an inventor of several patents related to novel biodegradable multi-block copolymers and their application in parenteral drug delivery and drug eluting implants. Prior to founding InnoCore in 2004, he worked for Polyganics, a venture capital funded biosurgical start-up company, where he played a key role in developing the company and managed the pre-clinical and clinical development of novel bioresorbable implants and tissue regeneration products in the fields of peripheral nerve repair and general surgery. He holds a MSc degree in Polymer Sciences and a PhD in Pharmaceutical Technology and Biopharmacy, both from the University of Groningen in The Netherlands. Email: r.steendam@innocorepharma.com.